Gr-1 Ab Administered after Bone Marrow Transplantation plus Thymus Transplantation Suppresses Tumor Growth by Depleting Granulocytic Myeloid-Derived Suppressor Cells

Ming Shi1,2, Ming Li1, Yunze Cui1,3, Yasushi Adachi1,4, Susumu Ikehara1 *

1 Department of Stem Cell Disorders, Kansai Medical University, Hirakata, Osaka, Japan, 2 Department of Occupational and Environmental Health, School of Public Health, Guangdong Medical College, Dongguan, Guangdong, China, 3 JIMRO Co., Ltd., Takasaki, Gunma, Japan, 4 Division of Clinical Pathology, Toyooka Hospital, Toyooka, Hyogo, Japan

Abstract

It has been shown that allogeneic intra-bone marrow–bone marrow transplantation (IBM-BMT) plus thymus transplantation (TT) is effective in treating recipients with malignant tumors. Although TT increases the percentage of T cells in the early term after BMT, the myeloid-derived suppressor cells (MDSCs) are still the dominant population. We used the Gr-1 Ab to deplete the granulocytic MDSCs (G-MDSC) in tumor-bearing mice that had received BMT+TT. Two weeks after the BMT, the mice injected with Gr-1 Ab showed smaller tumors than those in the control group. In addition, Gr-1 Ab significantly increased the percentages and numbers of CD4+ and CD8+ T cells, and decreased the percentages and numbers of MDSCs and G-MDSCs. No side effects of the Gr-1 Ab on recipient or donor thymus were observed. These findings indicate that Gr-1 Ab administered after BMT+TT may enhance the effectiveness of tumor suppression.

Citation: Shi M, Li M, Cui Y, Adachi Y, Ikehara S (2014) Gr-1 Ab Administered after Bone Marrow Transplantation plus Thymus Transplantation Suppresses Tumor Growth by Depleting Granulocytic Myeloid-Derived Suppressor Cells. PLoS ONE 9(5): e97908. doi:10.1371/journal.pone.0097908

Editor: Pranela Rameshwar, Rutgers - New Jersey Medical School, United States of America

Received February 18, 2014; Accepted April 25, 2014; Published May 21, 2014

Copyright: © 2014 Shi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was mainly supported by the Otsuka Pharmaceutical Company, Ltd., and by grants from the Research on Allergic Disease and Immunology Committee from the Health and Labour Sciences Research of the Ministry of Health, Labour and Welfare. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have the following interests. YC is employed by JIMRO Co., Ltd. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

* E-mail: ikehara@hirakata.kmu.ac.jp

Introduction

Allogeneic bone marrow transplantation (allo-BMT) has been used as a potentially curative therapy for not only leukemias, immunodeficiencies, and autoimmune diseases but also solid malignant tumors. Radiotherapy and/or chemotherapy performed as a conditioning regimen for BMT are prerequisites for suppressing host immunity and to reduce the tumor burden. The conditioning regimen also induces tissue damage and the release of a storm of proinflammatory cytokines. The proinflammatory responses, especially T-cell proliferation and cytokine production [4]. Studies have shown that MDSCs accumulate in most patients and experimental animals with cancer [5,6]. In mice these cells are defined as Gr-1+CD11b+ cells, and consist of two major subsets: Ly6G+Ly6Clow granulocytic (G-MDSCs) and Ly6G-Ly6Chigh monocytic (M-MDSCs) cells [7]. Inhibition of tumor growth was observed by depleting the G-MDSCs using the Gr-1 (RB6-8C5) Ab [8]. In this study, we investigate the influence of Gr-1 Ab administration on tumor suppression after allo-BMT+TT.

Materials and Methods

Mice

C57BL/6 (B6) and BALB/c mice were purchased from Shimizu Laboratory Supplies (Shizuoka, Japan). 8–12-week-old male mice were used for BMT. For TT, B6 mice were sacrificed one day after birth to obtain newborn thymuses. All the mice were maintained...
in a specific pathogen-free room. The Committee on the Ethics of Animal Experiments of Kansai Medical University approved our experiments. All protocols (11–142) for these animal experiments were performed in accordance with the Guidelines for Animal Experimentation, Kansai Medical University.

Inoculation of tumor cells

One day before the inoculation of tumor cells, the recipients (BALB/c mice) underwent total-body irradiation (3 Gy) using a 137Cs irradiator (Gammacell 40 Exactor; MDS Nordion International). The next day, Meth-A cells (2 × 10^5 in 50 ul PBS) were subcutaneously inoculated into the right flank of these mice.

Experimental protocol

Ten days after the inoculation of tumor cells, the BALB/c mice were irradiated with 7 Gy. The next day, the bone marrow cells (BMCs) were prepared by flushing them from the medullary cavities of the femurs and tibias of B6 mice with phosphate-buffered saline (PBS). The BMCs (1 × 10^7) were then injected directly into the tibial cavity of the recipient mice via the intrabone-marrow route. For TT and Gr-1 groups, one newborn thymus was simultaneously transplanted under the renal capsule in the recipients with BMT. From Day 5, recipient mice in the Gr-1 and TT groups were injected with 5 ug Gr-1 or its isotype Ab respectively every other day. The tumor diameter was measured every 2 or 3 days.

Reagents, flow cytometric analysis and cell number calculation

The antibodies (Abs) used in this study were as follows: purified rat anti-mouse Gr-1 Ab (Biolegend); fluorescein isothiocyanate (FITC) conjugated anti-mouse Gr-1 and H-2Kb Ab; phycoerythrin (PE) conjugated anti-mouse H-2Kd, CD4, CD8 and CD11b Ab; peridinin chlorophyll protein (PerCP)-Cy5.5 conjugated anti-mouse CD45 Ab (BD Pharmingen, San Diego, CA). Samples for flow cytometry were analyzed using a FACSCalibur flow cytometer (BD Biosciences). We counted the total numbers of nuclear cells in the peripheral blood using an SF-3000 autoanalyzer (Sysmex). The numbers of CD4+ T cells, CD8+ T cells, MDSC and G-MDSCs per ul were calculated by using the total cell number and percentage.

Statistical analysis

The results are represented as means ± SD. The Student’s t test was used to determine any statistical significance. A p-value of < 0.05 was considered to be a significant difference.

Results

Relationship between tumor size and the percentage of MDSCs or G-MDSCs

To address the relationship between tumor size and MDSCs, Meth-A cells were inoculated into BALB/c mice subcutaneously. MDSCs were defined as Gr-1+CD11b+ cells. Two weeks later, MDSCs of the peripheral blood were analyzed. The proportion of Gr-1+CD11b+ cells increased dramatically in mice with larger tumors. A size-dependent percentage of MDSCs was observed in these mice (Fig. 1A). Youn JI et al have reported that the...
population of G-MDSCs, but not M-MDSCs, was predominant in most tumor models and that it suppressed T cell proliferation [7]. Therefore, we analyzed the percentage of G-MDSCs in the peripheral blood. Tumor bearing mice showed a high proportion of G-MDSCs, and the trend toward increasing numbers of G-MDSCs was consistent with that of MDSCs (Fig. 1B). The evaluated percentages of MDSCs and G-MDSCs in the mice inoculated with Meth-A cells suggested that these cells might be used for suppressing tumor growth.

G-MDSC-depletion using Gr-1 Ab more effective in suppressing tumors when combined with allo-BMT+TT

We have shown that allogeneic IBM-BMT plus newborn TT is effective in tumor suppression. One of the mechanisms is that TT increases the percentage of CD4⁺ T cells in the short term (5 or 7 days) after BMT. However, no significant effects on CD8⁺ T cells were observed [9,10]. As reconstitution of the myeloid lineage is much faster than that of the T lineage cells, and G-MDSCs can suppress CD8⁺ T cell proliferation and IFN-γ production, we tried to deplete the G-MDSCs using the Gr-1 Ab [7,11]. The choice for the optimal dose of Gr-1 Ab was one that would effectively deplete the G-MDSCs from the peripheral blood by about 10 days. Preliminary experiments of different doses of Gr-1 Ab treatment showed that the administration of 5 ug Gr-1 (RB6-8C5) Ab every other day could meet this requirement due to the low cell number in the peripheral blood soon after BMT. From Day 5, some mice that had received the allo-BMT+TT combination were injected with 5 ug Gr-1 (RB6-8C5) Ab every other day. As with our previous results, the tumors were significantly smaller in the mice treated with allo-BMT+TT than in those treated with allo-BMT alone. The mice administered the Gr-1 Ab showed the greatest degree of tumor regression (Fig. 2). Since the use of Gr-1 Ab to deplete G-MDSCs has been reported to inhibit the growth of tumors, these results suggested that Gr-1 Ab could be used not only alone but also combined with allo-BMT+TT [8].

Gr-1 Ab increased the percentage and number of T cells

The presence of both donor CD4⁺ and CD8⁺ T cells has been reported to be critical in allo-BMT against murine solid tumors [12,13]. We therefore analyzed the peripheral blood two weeks after BMT and found that the percentages and numbers of CD4⁺ and CD8⁺ T cells in the Gr-1 group were significantly higher than those in the TT and BMT groups (Fig. 3A and B), suggesting that the administration of Gr-1 Ab contributed to the tumor suppression by increasing the percentage and number of T cells. As MDSCs and G-MDSCs have stimulated interest as a therapeutic target as a result of their ability to suppress T cell immune responses, these two subsets were also analyzed [14,15]. The results showed that the percentages and numbers of MDSCs and G-MDSCs in the Gr-1 group decreased significantly (Fig. 3C-E). These data indicate that the Gr-1 Ab injection ablated, at least

Figure 3. Gr-1 Ab increased the percentages and numbers of CD4⁺ and CD8⁺ T cells, and decreased the percentages and numbers of MDSCs and G-MDSCs two weeks after BMT. Recipient mice were sacrificed two weeks after BMT. The percentages and numbers of CD4⁺ T (A), CD8⁺ T (B), MDSCs (C) and G-MDSCs (D) in the peripheral blood were analyzed by FACS and symex. Representative FACS phenotypes of MDSCs (E). The recipients in all groups showed full donor chimerism (>98%, data not shown). *p<0.05, **p<0.01.
doi:10.1371/journal.pone.0097908.g003

Gr-1 Ab Suppresses Tumor Growth
transiently, the immune suppressive capacity of the G-MDSCs subsets.

Gr-1 Ab has no side effects on recipient or transplanted thymus

In tumor-bearing mammals, including mice and humans, T-cell function decreases due to involution of the thymus. TT combined with BMT is one strategy to restore T-cell function [16]. Gr-1 Ab improved the percentage of both CD4⁺ and CD8⁺ T cells in the allo-BMT+TT setting. Since factors that affect T cell reconstitution may impair the recovery of recipient thymus and development of transplanted thymus, we examined the effects of Gr-1 Ab on these thymuses [10]. The recipient thymus and transplanted thymus were removed for histological diagnosis and FACS analysis after the peripheral blood had been collected. Recipient and transplanted thymuses in the Gr-1 group were similar to those in the TT group, and histologically displayed well-defined cortical and medullary areas and phenotypically showed similar distribution of CD4⁺ and CD8⁺ T cells two weeks after BMT (Fig. 4A and B). These data suggest that the Gr-1 Ab has no side effects on the recovery of the recipient thymus and the development of the transplanted thymus.

Discussion

In this study, we examined the anti-tumor effects of Gr-1 Ab administered after allo-BMT+TT. Gr-1 Ab increased the percentages and numbers of CD4⁺ and CD8⁺ T cells, and decreased the percentage and number of G-MDSCs. Tumors in the Gr-1 group were smaller than in the BMT and TT groups.

The conditioning regimen for BMT reduced the tumor burden and produced lots of cytokines that have a wide range of biological effects. Some cytokines, such as TNF-α, have anti-tumor effects and could be of benefit for tumor suppression after BMT [1].

Figure 4. Gr-1 Ab has no side effects on recipient or transplanted thymus. Recipient mice were sacrificed two weeks after BMT. The recipient and donor thymuses were collected for HE staining and FACS analysis. Representative histological findings (A) and FACS phenotypes (B) are shown. Macroscopic findings, original magnification 100×. Cells analyzed for CD4⁺ and CD8⁺ expression were first gated by CD45⁺ cells.

doi:10.1371/journal.pone.0097908.g004
Gr-1 Ab Suppresses Tumor Growth

Meanwhile, IL-1 and IL-6 contributed to MDSC accumulation, MDSCs not only suppressing T-cell function but also inducing T-cell apoptosis [17,18,19]. The combination of allo-BMT+IT has been proven to be a novel strategy for suppressing tumor growth [16], this strategy restoring T-cell function and improving the percentage of CD4+ (but not CD8+) T cells in the short term after BMT [9]. Methods to prevent the impairment of MDSCs on T cells after BMT should be explored. Gr-1 Ab is used to reduce the level of G-MDSCs and thus inhibit tumor growth [8]. Therefore we wonder whether the administration of Gr-1 Ab after BMT would improve the anti-tumor effects. Our results showed that the percentage and number of G-MDSCs two weeks after BMT decreased significantly due to the injection of Gr-1 Ab (Fig. 3D). In addition, the percentages and numbers of CD4+ and CD8+ T cells were increased. These data suggested that Gr-1 Ab benefited TT transiently ablated by Gr-1 Ab injection, but Gr-1 Ab also triggered myeloid cells in the bone marrow, inducing myelopoiesis [20]. Therefore, the process of Gr-1 Ab administration in our experiment was limited since we only continued observations for two weeks after the BMT. Longer-term observation should thus be explored.

The tumor suppression seen after BMT involves a number of mechanisms. Both T cells and G-MDSCs play important roles in the immune system, and both are reconstituted by donor transplants (from BMCs or TT). The administration of Gr-1 Ab helps to suppress tumor growth by depleting the G-MDSCs and increasing the percentage and number of T cells, and may thus represent a new choice for more successfully inhibiting tumor growth.

Acknowledgments

We thank Hilary Eastwick-Field and Keiko Ando for their help in the preparation of this manuscript. We also thank Aiko Kitajima for excellent technical assistance regarding morphology.

Author Contributions

Conceived and designed the experiments: MS ML SI. Performed the experiments: MS ML YC. Analyzed the data: MS ML YA. Contributed reagents/materials/analysis tools: MS ML SI. Wrote the paper: MS SI.

References

1. Ferrara JL, Levine JE, Reddy P, Holler E (2009) Graft-versus-host disease. Lancet 373: 1550–1561.
2. Welniak LA, Blazar BR, Murphy WJ (2007) Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 25: 139–170.
3. Gabriovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162–174.
4. Youn JI, Gabriovich DI (2010) The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 40: 2969–2975.
5. Ahmand B, Clark J, Nikitina E, van Beynen J, English NR, et al. (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166: 678–689.
6. Sussanbori Y, Uchida S, Kurachi M, Shimaoka T, Tankadje JE, et al. (2008) Chemokine-mediated rapid turnover of myeloid-suppressor cells in tumor-bearing mice. Blood 111: 5457–5466.
7. Youn JI, Nagaraj S, Collazo M, Gabriovich DI (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181: 5791–5802.
8. Pekarsk LA, Staer BA, Toleldano AV, Schreiber H (1995) Inhibition of tumor growth by elimination of granulocytes. J Exp Med 181: 435–440.
9. Ryu T, Hosaka N, Miyake T, Cui W, Nishida T, et al. (2008) Transplantation of newborn thymus plus hematopoietic stem cells can rescue supralethally irradiated mice. Bone Marrow Transplant 41: 659–666.
10. Shi M, Li M, Cui Y, Liu L, Adachi Y, et al. (2013) CD4+T cell-depleted lymphocyte infusion impairs neither the recovery of recipient thymus nor the development of transplanted thymus. J Immunol 190: 2976–2983.
11. Zhao F, Obermann S, von Waiselerski R, Haile L, Mann MP, et al. (2009) Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology 128: 141–149.
12. Kamiryo Y, Eto M, Yamada H, Yajima T, Harano M, et al. (2009) Donor CD4+ T cells are critical in allogeneic stem cell transplantation against murine solid tumor. Cancer Res 69: 5151–5158.
13. Suzuki Y, Adachi Y, Minamino K, Zhang Y, Iwasaki M, et al. (2005) A new strategy for treatment of malignant tumor: intra-bone marrow-bone marrow transplantation plus CD4+ donor lymphocyte infusion. Stem Cells 23: 363–370.
14. Sica A, Bronne V (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155–1166.
15. Serroul P, Borrello I, Bronne V (2006) Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16: 55–65.
16. Rehara S (2011) Thymus transplantation for treatment of cancer: lessons from murine models. Expert Rev Clin Immunol 7: 205–211.
17. Song X, Krelin Y, Dvorkin T, Bjorkdahl O, Segal S, et al. (2005) CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol 175: 4200–4208.
18. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S (2006) Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 176: 284–290.
19. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, et al. (2007) Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67: 10019–10026.
20. Ribecki E, Leenen PJ, Lutz MB (2009) Gr-1 antibody induces STAT signaling, macrophage marker expression and abrogation of myeloid-derived suppressor cell activity in BM cells. Eur J Immunol 39: 3538–3551.